应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
TEVA 梯瓦制药
休市中 11-20 16:00:00 EST
39.23
+0.69
+1.79%
盘后
38.71
-0.52
-1.32%
19:42 EST
最高
39.91
最低
38.30
成交量
680.94万
今开
38.46
昨收
38.54
日振幅
4.18%
总市值
457.03亿
流通市值
432.96亿
总股本
11.65亿
成交额
2.68亿
换手率
0.62%
流通股本
11.04亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读|梯瓦制药盘中下跌4.19%,研发负责人离任引发市场谨慎
行情直击 · 11-19 23:07
异动解读|梯瓦制药盘中下跌4.19%,研发负责人离任引发市场谨慎
传奇投资人德鲁肯米勒Q3持仓:AI投资组合“大换血” 建仓黄金股释放多元化布局信号
智通财经 · 11-17
传奇投资人德鲁肯米勒Q3持仓:AI投资组合“大换血” 建仓黄金股释放多元化布局信号
异动解读|梯瓦制药盘中下跌3.06%,Igalmi获批居家使用后资金选择兑现
行情直击 · 11-17
异动解读|梯瓦制药盘中下跌3.06%,Igalmi获批居家使用后资金选择兑现
梯瓦制药目标2030年创新药收入达60亿至70亿美元
格隆汇 · 11-11
梯瓦制药目标2030年创新药收入达60亿至70亿美元
异动解读|梯瓦制药盘中上涨5.45%,三季度创新药收入高增并上调全年展望
行情直击 · 11-03
异动解读|梯瓦制药盘中上涨5.45%,三季度创新药收入高增并上调全年展望
美股异动 | 三季度创新药营收同比增长33% 梯瓦制药(TEVA.US)涨逾4%
智通财经 · 11-03
美股异动 | 三季度创新药营收同比增长33% 梯瓦制药(TEVA.US)涨逾4%
梯瓦制药首席执行官弗朗西斯:尽管品牌药业务有所增长,但由于生物类似药管线的推进,仿制药业务将继续增长并保持盈利。新推出的
智通财经 · 11-03
梯瓦制药首席执行官弗朗西斯:尽管品牌药业务有所增长,但由于生物类似药管线的推进,仿制药业务将继续增长并保持盈利。新推出的
梯瓦制药Q3创新品牌表现亮眼,上调2026年业绩展望
格隆汇 · 11-03
梯瓦制药Q3创新品牌表现亮眼,上调2026年业绩展望
梯瓦制药(TEVA)Q3非GAAP每股收益0.86美元 创新药合计营收11亿美元同比增33%
金吾财讯 · 11-03
梯瓦制药(TEVA)Q3非GAAP每股收益0.86美元 创新药合计营收11亿美元同比增33%
梯瓦制药第三季度营收44亿美元,市场预估42.4亿美元。
智通财经 · 11-03
梯瓦制药第三季度营收44亿美元,市场预估42.4亿美元。
梯瓦制药股价跌幅扩大至5.4%,此前该公司停止了一项二期研究。
智通财经 · 11-02
梯瓦制药股价跌幅扩大至5.4%,此前该公司停止了一项二期研究。
财报前瞻 | 梯瓦制药本季度营收预计减2.81%,机构观点偏多
财报Agent · 10-27
财报前瞻 | 梯瓦制药本季度营收预计减2.81%,机构观点偏多
异动解读|梯瓦制药盘中上涨5.05%,FDA批准WELTRUZA治疗精神分裂症
行情直击 · 10-09
异动解读|梯瓦制药盘中上涨5.05%,FDA批准WELTRUZA治疗精神分裂症
三星生物制药与梯瓦制药扩大战略合作,推进至多六款候选生物类似药研发.
智通财经 · 10-01
三星生物制药与梯瓦制药扩大战略合作,推进至多六款候选生物类似药研发.
梯瓦制药新数据:Uzedy®(利培酮)长效针剂在精神分裂症治疗依从性上优于同类药物,同时降低急诊与医疗成本
美股速递 · 09-19
梯瓦制药新数据:Uzedy®(利培酮)长效针剂在精神分裂症治疗依从性上优于同类药物,同时降低急诊与医疗成本
异动解读|梯瓦制药盘中上涨5.07%,普通股正式登陆纽交所直接交易
行情直击 · 09-15
异动解读|梯瓦制药盘中上涨5.07%,普通股正式登陆纽交所直接交易
梯瓦制药(TEVA)完成49亿美元等值优先票据定价 募资用于置换多笔存量债券
金吾财讯 · 09-10
梯瓦制药(TEVA)完成49亿美元等值优先票据定价 募资用于置换多笔存量债券
梯瓦制药美股盘前上涨3.5%,免疫疾病药物中期试验达标
美股速递 · 09-02
梯瓦制药美股盘前上涨3.5%,免疫疾病药物中期试验达标
梯瓦制药美国上市盘前股价上涨3.5%,此前该公司免疫紊乱药物在中期试验中达到主要终点。
智通财经 · 09-02
梯瓦制药美国上市盘前股价上涨3.5%,此前该公司免疫紊乱药物在中期试验中达到主要终点。
梯瓦制药(TEVA)与Royalty Pharma(RPRX)合作抗体药物TEV'408迎重大临床突破
金吾财讯 · 09-02
梯瓦制药(TEVA)与Royalty Pharma(RPRX)合作抗体药物TEV'408迎重大临床突破
加载更多
公司概况
公司名称:
梯瓦制药
所属市场:
NYSE
上市日期:
--
主营业务:
Teva Pharmaceutical Industries Limited于1944年2月13日在以色列注册成立。该公司是一家全球性生物制药公司,拥有重要的仿制药业务,在全球约57个市场开展业务。它专注于神经科学和免疫学领域的创新,同时提供复杂的仿制药、生物仿制药和药房品牌,以满足患者的需求。
发行价格:
--
{"stockData":{"symbol":"TEVA","market":"US","secType":"STK","nameCN":"梯瓦制药","latestPrice":39.23,"timestamp":1795208400000,"preClose":38.54,"halted":0,"volume":6809403,"hourTrading":{"tag":"盘后","latestPrice":38.7138,"preClose":39.23,"latestTime":"19:42 EST","volume":30016,"amount":1177351.619,"timestamp":1795221751543,"change":-0.5162,"changeRate":-0.013158,"amplitude":0.013668},"delay":0,"changeRate":0.017903476907109438,"floatShares":1103647796,"shares":1165000000,"eps":0.42685,"marketStatus":"休市中","change":0.69,"latestTime":"11-20 16:00:00 EST","open":38.46,"high":39.91,"low":38.3,"amount":267661405.122651,"amplitude":0.041775,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.42685,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1795424400000},"marketStatusCode":7,"adr":0,"adrRate":1,"exchange":"NYSE","adjPreClose":38.54,"preHourTrading":{"tag":"盘前","latestPrice":38.46,"preClose":38.54,"latestTime":"09:29 EST","volume":31921,"amount":1248373.586383,"timestamp":1795184988870,"change":-0.08,"changeRate":-0.002076,"amplitude":0.024084},"postHourTrading":{"tag":"盘后","latestPrice":38.7138,"preClose":39.23,"latestTime":"19:42 EST","volume":30016,"amount":1177351.619,"timestamp":1795221751543,"change":-0.5162,"changeRate":-0.013158,"amplitude":0.013668},"volumeRatio":0.8243399563234012,"impliedVol":0.3724,"impliedVolPercentile":0.3745},"requestUrl":"/m/hq/s/TEVA","defaultTab":"news","newsList":[{"id":"1107731864","title":"异动解读|梯瓦制药盘中下跌4.19%,研发负责人离任引发市场谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1107731864","media":"行情直击","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107731864?lang=zh_cn&edition=full","pubTime":"2026-11-19 23:07","pubTimestamp":1795100828,"startTime":"0","endTime":"0","summary":"11月19日,梯瓦制药盘中下跌4.19%,报40.56美元/股,成交额5204.24万美元。消息面上,公司宣布首席医疗官兼全球研发执行副总裁Eric Hughes将离职并赴外部任职,未来数月将协助交接;创新药与临床开发负责人David Gardiner将暂任研发过渡负责人,直至永久继任者到位。公司同时表示,战略、研发优先级及经营预期维持不变,且已启动继任者遴选。但在公司近期刚举行研发日、持续强化创新药叙事背景下,核心研发高管变动仍令资金偏向谨慎。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"研发负责人离任,梯瓦制药股价下挫","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148752597","title":"传奇投资人德鲁肯米勒Q3持仓:AI投资组合“大换血” 建仓黄金股释放多元化布局信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1148752597","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148752597?lang=zh_cn&edition=full","pubTime":"2026-11-17 10:06","pubTimestamp":1794881203,"startTime":"0","endTime":"0","summary":"传奇投资人、杜肯资本创始人斯坦利·德鲁肯米勒旗下全球顶级家族办公室Duquesne Family Office递交了截至2026年9月30日的第三季度持仓报告。数据显示,Duquesne Family Office第三季度持仓总市值为44.7亿美元,上一季度总市值为52.1亿美元。Duquesne Family Office在第三季度的持仓组合中新增了17只个股,增持了16只个股。存储芯片商 $希捷科技$位列第二,持仓约34.2万股,持仓市值约为3.15亿美元,占投资组合比例为7.05%,较上季度的持仓数量大增180.16%。第三季度新建仓标的合计约5.03亿美元。","market":"us","thumbnail":"https://community-static.tradeup.com/news/1cc62a887218bf445d8990436704c6f2","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/1cc62a887218bf445d8990436704c6f2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1524124.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BU","FOXA","SNX","PLTY","WDC","PLTA","AMAA","LOFF","SNDK","LRCU","SNXX","RDTL","GOGL","WDCX","APP","SNDC","GOOL","GOU","LRCX","STM","STXX","RDDC","SPCH","NSIT","SNDQ","DSPC","TTMI","GOOGL","NEMG","NEM","B","GOOX","TSMY","TTMX","GOOW","STSM","PLOO","SPAL","GOOY","AMZN","SPCM","TSM","PLTZ","SPCQ","SSPC","SNDU","YPF","STXL","YSPC","PLTG","TWSC","AMZY","SPCF","UNX","SEA.AU","TSMU","SPAX","AEM","PLTD","ELOL","PLTL","STXU","WDCC","PTIR","LOFD","PLTU","PLTW","AZYY","U","RDYY","TSMZ","SPCG","STX","GGLS","NWMX","PLYY","TSMX","SPCU","INSM","HUM","PLTR","GOOP","APPC","GGLL","AMZZ","APPX","KRSA","PLTI","EWZ","LIN","AMZD","TSMG","STMX","RDDT","LRCC","SGI","AMZU","SNDG","AMZP","SPCX","AMZO","NTRA","SNK","TEVA","AMZG","TMO","AMZW"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1119137890","title":"异动解读|梯瓦制药盘中下跌3.06%,Igalmi获批居家使用后资金选择兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=1119137890","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119137890?lang=zh_cn&edition=full","pubTime":"2026-11-17 02:46","pubTimestamp":1794854814,"startTime":"0","endTime":"0","summary":"11月17日,梯瓦制药盘中下跌3.06%,报43.16美元/股,成交额1.67亿美元。最新消息面上,公司美国关联方宣布,FDA已批准Igalmi舌下含片用于居家场景,适用于与精神障碍相关的激越治疗。该产品对应资产BXCL501,梯瓦于10月下旬完成收购相关资产,交易包含5750万美元预付款及最高6750万美元或有付款。此次获批强化了其中枢神经产品布局,但股价回落,显示市场在近期财报上调指引、创新药收入增长后出现阶段性获利了结。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"梯瓦制药盘中下跌,Igalmi获批后资金兑现","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682070853","title":"梯瓦制药目标2030年创新药收入达60亿至70亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682070853","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682070853?lang=zh_cn&edition=full","pubTime":"2026-11-11 22:02","pubTimestamp":1794405762,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4557","LU2324357040.USD","LNGR","BK4007","MEDX","IBBQ","BK4559","LU1983299246.USD","BK4588","PRTO","BK4584","TEVA","BK4596","BK4585","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111378641","title":"异动解读|梯瓦制药盘中上涨5.45%,三季度创新药收入高增并上调全年展望","url":"https://stock-news.laohu8.com/highlight/detail?id=1111378641","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111378641?lang=zh_cn&edition=full","pubTime":"2026-11-03 23:16","pubTimestamp":1793718995,"startTime":"0","endTime":"0","summary":"11月3日,梯瓦制药盘中上涨5.45%,报42.9453美元,成交额1.05亿美元。消息面上,公司第三季度非GAAP每股收益0.86美元,高于市场预期的0.72美元;营收44亿美元,也高于预期。其AUSTEDO、AJOVY和UZEDY三大创新药合计营收约11亿美元,按固定汇率计算同比增长33%。同时,公司上调全年营收指引至167亿至170亿美元,并将调整后每股收益指引区间下限上调至1.92美元。尽管调整后EBITDA指引区间上沿较此前收窄,但创新品牌放量与全年收入预期改善,仍构成当日股价上行动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"梯瓦制药上涨,创新药收入高增","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680819778","title":"美股异动 | 三季度创新药营收同比增长33% 梯瓦制药(TEVA.US)涨逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680819778","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680819778?lang=zh_cn&edition=full","pubTime":"2026-11-03 23:09","pubTimestamp":1793718554,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["TEVA","BK4557","BK4007","LNGR","LU1983299246.USD","MEDX","IBBQ","BK4559","BK4588","LU2324357040.USD","BK4584","BK4566","BK4596","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680172091","title":"梯瓦制药首席执行官弗朗西斯:尽管品牌药业务有所增长,但由于生物类似药管线的推进,仿制药业务将继续增长并保持盈利。新推出的","url":"https://stock-news.laohu8.com/highlight/detail?id=2680172091","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680172091?lang=zh_cn&edition=full","pubTime":"2026-11-03 22:55","pubTimestamp":1793717700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBB","BK4596","BK4007","TEVA","XPH","IE00B5TLWC47.USD","BK4557","BK4559","BK4588","LU1992135472.HKD","LU2272731782.SGD","LU2322448957.HKD","PPH","LU2272731865.HKD","LU1983299246.USD","BK4585","LU2322448791.USD","BK4584","LU1992135399.USD","BK4566","LU2272731600.USD","LU2473716301.USD","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680724838","title":"梯瓦制药Q3创新品牌表现亮眼,上调2026年业绩展望","url":"https://stock-news.laohu8.com/highlight/detail?id=2680724838","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680724838?lang=zh_cn&edition=full","pubTime":"2026-11-03 21:25","pubTimestamp":1793712310,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1983299246.USD","BK4596","BK4559","BK4557","LU2324357040.USD","BK4007","TEVA","BK4566","BK4585","BK4588","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680292647","title":"梯瓦制药(TEVA)Q3非GAAP每股收益0.86美元 创新药合计营收11亿美元同比增33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680292647","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680292647?lang=zh_cn&edition=full","pubTime":"2026-11-03 20:59","pubTimestamp":1793710749,"startTime":"0","endTime":"0","summary":"金吾财讯 | 梯瓦制药 公布2026年第三季度财报,公司非GAAP每股收益0.86美元,超出市场预期0.14美元;营收44亿美元,同比下降2%,超出市场预期1.7亿美元。创新药AUSTEDO、AJOVY和UZEDY合计实现约11亿美元营收,按固定汇率计算同比增长33%,梯瓦上调这三大品牌2026财年营收展望。公司披露2026财年业绩指引:营收167-170亿美元,市场普遍预期166.6亿美元;非GAAP摊薄每股收益1.92-2.11美元,市场普遍预期2.09美元;调整后EBITDA为42.3-44.3亿美元;自由现金流21-24亿美元。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"307932","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","IBBQ","MEDX","TEVA","159992","UUP","UDN","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680725643","title":"梯瓦制药第三季度营收44亿美元,市场预估42.4亿美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2680725643","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680725643?lang=zh_cn&edition=full","pubTime":"2026-11-03 20:07","pubTimestamp":1793707660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","TEVA","BK4007","LU2324357040.USD","BK4559","BK4557","BK4584","BK4566","BK4588","LU1983299246.USD","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680116757","title":"梯瓦制药股价跌幅扩大至5.4%,此前该公司停止了一项二期研究。","url":"https://stock-news.laohu8.com/highlight/detail?id=2680116757","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680116757?lang=zh_cn&edition=full","pubTime":"2026-11-02 21:02","pubTimestamp":1793624569,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1983299246.USD","BK4584","TEVA","LU2324357040.USD","BK4007","BK4588","BK4596","BK4566","BK4557","BK4559","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124797283","title":"财报前瞻 | 梯瓦制药本季度营收预计减2.81%,机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1124797283","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124797283?lang=zh_cn&edition=full","pubTime":"2026-10-27 08:27","pubTimestamp":1793060870,"startTime":"0","endTime":"0","summary":"梯瓦制药将于2026年11月03日美股盘前发布最新季度财报,市场聚焦新品放量及盈利修复路径。市场一致预期本季度公司营收约42.31亿美元,同比-2.81%;调整后每股收益约0.72美元,同比+9.20%;EBIT约11.47亿美元,同比+0.51%。关于毛利率与净利润或净利率的具体预测未获取,未能纳入本节。上一季度公司营收41.42亿美元,同比-0.81%;毛利率51.98%;归母净亏损5.76亿美元,净利率-13.91%;调整后每股收益0.02美元,同比-96.97%。机构观点以看多为主。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | 梯瓦制药本季度营收预计减2.81%,机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189732481","title":"异动解读|梯瓦制药盘中上涨5.05%,FDA批准WELTRUZA治疗精神分裂症","url":"https://stock-news.laohu8.com/highlight/detail?id=1189732481","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189732481?lang=zh_cn&edition=full","pubTime":"2026-10-09 21:36","pubTimestamp":1791552965,"startTime":"0","endTime":"0","summary":"10月9日,梯瓦制药盘中上涨5.05%,报41.22美元/股,成交额9075.84万美元。消息面上,美国FDA批准了该公司WELTRUZA用于成人精神分裂症治疗,该药为奥氮平长效皮下注射剂,每月一次给药,无需负荷剂量、口服补充或注射后监测,预计将在未来几周内在美上市。此次批准基于其Solaris III期试验,数据显示疾病严重程度显著降低,个人与社会功能改善。此前,TD Cowen于10月1日对梯瓦制药给出买入评级,目标价55美元,反映市场对其创新管线和生物类似药商业化的持续关注。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"梯瓦制药盘中上涨,FDA批准精神分裂症新药","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672753398","title":"三星生物制药与梯瓦制药扩大战略合作,推进至多六款候选生物类似药研发.","url":"https://stock-news.laohu8.com/highlight/detail?id=2672753398","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672753398?lang=zh_cn&edition=full","pubTime":"2026-10-01 16:30","pubTimestamp":1790843422,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4559","BK4596","PPH","LU1992135472.HKD","BK4584","BBP","TEVA","BK4585","MRNY","EMXC","LU2322448957.HKD","IBB","BK4007","IE00B5TLWC47.USD","LU2272731865.HKD","LU1992135399.USD","LU2272731600.USD","BK4557","MRNX","LU2324357040.USD","BK4588","BK4566","XPH","LU2272731782.SGD","IBBQ","LU2322448791.USD","LU2473716301.USD","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173476954","title":"梯瓦制药新数据:Uzedy®(利培酮)长效针剂在精神分裂症治疗依从性上优于同类药物,同时降低急诊与医疗成本","url":"https://stock-news.laohu8.com/highlight/detail?id=1173476954","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173476954?lang=zh_cn&edition=full","pubTime":"2026-09-19 04:32","pubTimestamp":1789763533,"startTime":"0","endTime":"0","summary":"梯瓦制药最新公布的现实世界研究数据引发行业关注。数据显示,其旗下Uzedy(利培酮)长效注射剂在帮助精神分裂症患者维持治疗方面,表现出优于其他同类长效针剂的显著成效——不仅大幅提升患者持续用药率,还同步压低了急诊就医频次及整体医疗开支。梯瓦制药此番公布的数据,不仅是对自家产品疗效的背书,更是在为长效针剂在精神分裂症治疗版图中的定位加码。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA","BK4566","BK4559","BK4557","BK4596","BK4588","BK4007","BK4585","LU1983299246.USD","BK4584","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181129883","title":"异动解读|梯瓦制药盘中上涨5.07%,普通股正式登陆纽交所直接交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1181129883","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181129883?lang=zh_cn&edition=full","pubTime":"2026-09-15 00:27","pubTimestamp":1789403232,"startTime":"0","endTime":"0","summary":"9月15日,梯瓦制药盘中上涨5.07%,报38.97美元/股,成交额3820.02万美元。消息面上,梯瓦制药宣布其普通股已正式在纽约证券交易所开始直接交易,完成从美国存托凭证向普通股的转换,股票代码继续为\"TEVA\",同时在纽交所和特拉维夫交易所双重上市。公司表示,此举有望扩大投资者准入渠道并强化其在美国资本市场的地位。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"梯瓦制药转板纽交所,盘中强势上扬","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666560146","title":"梯瓦制药(TEVA)完成49亿美元等值优先票据定价 募资用于置换多笔存量债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560146","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666560146?lang=zh_cn&edition=full","pubTime":"2026-09-10 19:00","pubTimestamp":1789038049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 梯瓦制药 完成总规模约49亿美元等值优先票据的发行定价。本次发行共分为五个批次:10亿欧元2033年到期票据,票面利率4.25%;5亿欧元2036年到期票据,票面利率4.625%;10亿美元2034年到期票据,票面利率5.5%;10亿美元2037年到期票据,票面利率5.75%;12亿美元2032年到期票据,票面利率5.25%。梯瓦制药计划将本次募资净额,叠加公司现有现金,用于赎回存量债务、支付相关发行费用以及一般企业用途。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305896","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA","BK4566","BK4559","BK4557","BK4596","BK4588","BK4007","BK4585","LU1983299246.USD","BK4584","BNDW","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188485546","title":"梯瓦制药美股盘前上涨3.5%,免疫疾病药物中期试验达标","url":"https://stock-news.laohu8.com/highlight/detail?id=1188485546","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1188485546?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:13","pubTimestamp":1788351207,"startTime":"0","endTime":"0","summary":"梯瓦制药(Teva Pharmaceutical)在美国上市的股票在盘前交易中上涨了3.5%。此前,该公司宣布其治疗免疫系统疾病的药物在中期临床试验中达到了主要目标。这一消息提振了投资者信心,推动股价在盘前时段走高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4559","BK4596","BK4566","LU1983299246.USD","TEVA","BK4588","BK4585","BK4584","BK4007","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811810","title":"梯瓦制药美国上市盘前股价上涨3.5%,此前该公司免疫紊乱药物在中期试验中达到主要终点。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811810","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664811810?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:11","pubTimestamp":1788351064,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4557","LU2324357040.USD","BK4596","BK4584","IPOS","BK4566","BK4585","BK4559","TEVA","BK4007","BK4588","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664333811","title":"梯瓦制药(TEVA)与Royalty Pharma(RPRX)合作抗体药物TEV'408迎重大临床突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2664333811","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664333811?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:07","pubTimestamp":1788350836,"startTime":"0","endTime":"0","summary":"金吾财讯 | 梯瓦制药 与Royalty Pharma宣布,双方合作开发的抗白细胞介素-15抗体药物TEV'408在治疗成人乳糜泻的2a期临床试验中取得积极结果。在给药第8周时,与安慰剂组相比,TEV'408在统计学上显著且临床上有效地预防了由麸质诱发的肠道损伤。根据“乳糜泻症状日记”显示,接受TEV'408治疗的患者其胃肠道症状评分明显低于安慰剂组。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305631","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","IHE","BK4566","LU2324357040.USD","RPRX","BK4007","BK4584","TEVA","PBE","BK4557","BK4596","BK4585","LU1983299246.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tevapharm.com;ir.tevapharm.com","stockEarnings":[{"period":"1week","weight":-0.1184},{"period":"1month","weight":-0.0342},{"period":"3month","weight":0.0506},{"period":"6month","weight":0.1515},{"period":"1year","weight":0.6157},{"period":"ytd","weight":0.257}],"compareEarnings":[{"period":"1week","weight":-0.0856},{"period":"1month","weight":-0.1077},{"period":"3month","weight":-0.0991},{"period":"6month","weight":-0.0749},{"period":"1year","weight":0.0571},{"period":"ytd","weight":0.0116}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Teva Pharmaceutical Industries Limited于1944年2月13日在以色列注册成立。该公司是一家全球性生物制药公司,拥有重要的仿制药业务,在全球约57个市场开展业务。它专注于神经科学和免疫学领域的创新,同时提供复杂的仿制药、生物仿制药和药房品牌,以满足患者的需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.063449},{"month":2,"riseRate":0.357143,"avgChangeRate":-0.01732},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.019164},{"month":4,"riseRate":0.357143,"avgChangeRate":0.006451},{"month":5,"riseRate":0.5,"avgChangeRate":-0.00523},{"month":6,"riseRate":0.466667,"avgChangeRate":0.009278},{"month":7,"riseRate":0.6,"avgChangeRate":0.027757},{"month":8,"riseRate":0.266667,"avgChangeRate":-0.042226},{"month":9,"riseRate":0.466667,"avgChangeRate":-0.004542},{"month":10,"riseRate":0.466667,"avgChangeRate":-0.013755},{"month":11,"riseRate":0.6,"avgChangeRate":0.053286},{"month":12,"riseRate":0.571429,"avgChangeRate":0.030034}],"exchange":"NYSE","name":"梯瓦制药","nameEN":"Teva Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"梯瓦制药(TEVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供梯瓦制药(TEVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"梯瓦制药,TEVA,梯瓦制药股票,梯瓦制药股票老虎,梯瓦制药股票老虎国际,梯瓦制药行情,梯瓦制药股票行情,梯瓦制药股价,梯瓦制药股市,梯瓦制药股票价格,梯瓦制药股票交易,梯瓦制药股票购买,梯瓦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"梯瓦制药(TEVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供梯瓦制药(TEVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}